Skip to Content

Join the 'Vemlidy' group to help and get support from people like you.

Vemlidy News

Charlie Sheen's 2015 HIV Disclosure Spiked Use of Home Test Kits

Posted 6 days ago by Drugs.com

THURSDAY, May 18, 2017 – Soon after actor Charlie Sheen revealed his HIV-positive status back in late 2015, rates of at-home testing for the virus shot up to record levels, a new report shows. The study follows on 2016 research that found the the Internet was abuzz with millions more searches for HIV-related topics after the former "Two and a Half Men" star made the disclosure in November of 2015. In total, all English-language searches about HIV quadrupled beyond the usual number the day after Sheen's announcement, said a team from San Diego State University. Searches for information about HIV symptoms and testing were about six times higher than normal. And their follow-up research has now found that weekly sales of the HIV home-test kit OraQuick nearly doubled in the week after the announcement. "Charlie Sheen's disclosure is potentially the most significant domestic HIV prevention ... Read more

Related support groups: HIV Infection, Valtrex, Acyclovir, Valacyclovir, Ribavirin, Pre-Exposure Prophylaxis, Incivek, Zovirax, Baraclude, Famciclovir, Victrelis, Famvir, Viread, Daklinza, Kaletra, Entecavir, Ribasphere, Diagnosis and Investigation, Valcyte, Tenofovir

Is the AIDS Epidemic Winding Down in the U.S.?

Posted 7 days ago by Drugs.com

WEDNESDAY, May 17, 2017 – Could the United States be turning the corner on the AIDS epidemic? New research suggests it's possible. If certain targets are met, the rate of new infections may be down to 12,000 a year by 2025, which would mark a transition toward the end of the HIV/AIDS epidemic, the researchers said. "Achieving these targets will require a sustained and intensified national commitment to ending the epidemic," said study author Dr. Robert Bonacci, from Brigham and Women's Hospital in Boston. "But if the U.S. does achieve a reduction to 12,000 new HIV infections by 2025, it could mark an important turning point in the U.S. HIV epidemic: a decline in the total number of people living with HIV in the U.S., and the beginning of the end of the U.S. AIDS epidemic," he said in a hospital news release. It's crucial that the goals of the U.S. National HIV/AIDS Strategy (NHAS) are ... Read more

Related support groups: HIV Infection, Pre-Exposure Prophylaxis, Incivek, Baraclude, Victrelis, Viread, Kaletra, Tenofovir, Norvir, Entecavir, Telaprevir, Lamivudine, Boceprevir, Reyataz, Nevirapine, Prezista, Norvir Soft Gelatin, Hepsera, Abacavir, Zidovudine

Life Expectancy With HIV Nears Normal With Treatment

Posted 13 days ago by Drugs.com

WEDNESDAY, May 10, 2017 – Young adults with HIV who get treatment are living longer in North America and Europe, a new study finds. In fact, a 20-year-old with HIV who began antiretroviral treatment in 2008 or later and had a low viral load after a year of treatment has a life expectancy that's close to that of the general population – around 78 years old, the study found. But life expectancy for people with HIV mostly remains lower than that of the general population, according to the study published in The Lancet HIV. The researchers said their findings could help reduce stigmatization of people with HIV and help them get jobs and medical insurance. The study should also encourage newly diagnosed HIV patients to begin treatment as soon as possible and stick with it. "Our research illustrates a success story of how improved HIV treatments coupled with screening, prevention and ... Read more

Related support groups: HIV Infection, Valtrex, Acyclovir, Tamiflu, Valacyclovir, Ribavirin, Pre-Exposure Prophylaxis, Incivek, Zovirax, Baraclude, Famciclovir, Victrelis, Famvir, Oseltamivir, Viread, Kaletra, Valcyte, Entecavir, Tenofovir, Norvir

FDA Approves Gilead’s Vemlidy (tenofovir alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection

Posted 15 Nov 2016 by Drugs.com

FOSTER CITY, Calif.--(BUSINESS WIRE)--Nov. 10, 2016-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Vemlidy (tenofovir alafenamide, TAF) 25mg, a once-daily treatment for adults with chronic hepatitis B virus (HBV) infection with compensated liver disease. Vemlidy has a boxed warning in its product label regarding the risks of lactic acidosis/severe hepatomegaly with steatosis and post-treatment severe acute exacerbation of hepatitis B. See below for important safety information. Vemlidy is a novel, targeted prodrug of tenofovir that has demonstrated antiviral efficacy similar to and at a dose less than one-tenth that of Gilead’s Viread® (tenofovir disoproxil fumarate, TDF) 300mg. Data show that because Vemlidy has greater plasma stability and more efficiently delivers tenofovir to hepatocytes compared to Viread, it ca ... Read more

Related support groups: Hepatitis B, Viread, Tenofovir, Vemlidy, Tenofovir Alafenamide

Ask a Question

Further Information

Related Condition Support Groups

Hepatitis B

Vemlidy Patient Information at Drugs.com